Who makes Interferon beta-1b and Tacrolimus?

Interferon beta-1b and Tacrolimus is developed by Clinique de sclérose en plaques et neuromusculaire de l'Outaouais.

What development phase is Interferon beta-1b and Tacrolimus in?

Interferon beta-1b and Tacrolimus is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Interferon beta-1b and Tacrolimus

Clinique de sclérose en plaques et neuromusculaire de l'Outaouais · Phase 2 active Small molecule

At a glance

Generic name	Interferon beta-1b and Tacrolimus
Sponsor	Clinique de sclérose en plaques et neuromusculaire de l'Outaouais
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Combination Therapy of Betaseron-Prograf in Multiple Sclerosis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Interferon beta-1b and Tacrolimus CI brief — competitive landscape report
Interferon beta-1b and Tacrolimus updates RSS · CI watch RSS
Clinique de sclérose en plaques et neuromusculaire de l'Outaouais portfolio CI